Altogether, the study discussed in part III combined the three aforementioned advantages: (i) the addition of TSP to the samples as an HSA-binding competitor, (ii) the inclusion of only early-stage NSCLC patients, and (iii) the reduction in patient-to-patient variability by comparing paired pre- with postoperative plasma metabolite profiles. Here, ALB is linked to non-small cell lung carcinoma.